Amgen launched its adalimumab biosimilar - Amjevita ( FDA approved in 2016), has 2 different discounts— 55% or 5% below Humira's (list $6,922/mo). Another report says Amjevita 40mg given q 2wk will cost $40,497 - $85,494 annually https://t.co/iGtJUa991N https://t.co/PTPTUskUaa

1st there was combined Rheum-Derm or Rheum-Pulm clinics. Medscape reports new Rheum-Cardiology clinics at Cleveland Clinic, NYU, Brigham, Stanford. Useful in research, managing Rheum pts a) at hi CV risk, B) having procedures/surgery, c) risk reduction https://t.co/9AqujArSMT https://t.co/3ZVORt9gK9

FDA has approved the 1st BTK (Bruton’s tyrosine kinase) inhibitor (Jaypirca™ or pirtobrutinib) for adults with refractory mantle cell lymphoma. BTK inhibitors are also being developed for use in MS, RA, SLE, pemphigus & more https://t.co/gDHbcDpNnT https://t.co/oL0nldQ1fN

Last day for early bird pricing! https://t.co/KwQnDC4Pdz RheumNow Live is a 1.5-day long meeting that offers pre-learning modules, shorter, concise lectures with clinical context and audience input, more discussion time, and sessions that are relaxed and comprehensive. https://t.co/W4mqIyhgRS

Have you listened to last week's RheumNow podcast? Dr. Cush answers the question--is there such a thing as dry synovitis? https://t.co/Um0JhCfRDv https://t.co/rXOGWOEnlr

Pathogenic Impact of microRNA Cotargeting in Lupus A group of researchers from the Graduate School of Medicine at Nagoya University in Japan have discovered the impact of microRNA (miRNA) on inflammation in lupus in mice. https://t.co/j0TRgIaam6 https://t.co/HNJbsTfT7c

Study of 58 pediatric patients with Kikuchi-Fujimoto disease saw 15 (26%) with Macrophage Activation Syndr. KFD-MAS+ pts had signif. more skin rash (27%), Steroid Rx(80%), Dz recurrence (33%), lower cell counts (WBC, plt, lymphs) & higher LDH. https://t.co/GINlAJlEHi https://t.co/idhuaAo9T6

197 ANCA assoc Vasculitis pts in RAVE - treated w/ RTX or CTX, thenAZA. 18/22 severe infections occurred within 6 months. Predictors of severe infx included higher baseline CD19+B cells & PJP prophylaxis w/ TMP/SMX (both groups Rx RTX or CYC/AZA) https://t.co/YhNDCdJuof https://t.co/Fg8AOLtYbI

Advancing Telehealth in Rheumatology https://t.co/XZTkGQMImc https://t.co/QJjXzjAx5Q

Rheumatic Disease - IBD Overlap Nearly one in 10 patients with IBD also have rheumatologic disorders, meaning that specialists have to talk to each other to develop a treatment plan that works for both conditions, a researcher suggested. https://t.co/s3u9q8Sw9Y https://t.co/RjFyEcm6FA

AI Passes U.S. Medical Licensing Exam Two artificial intelligence (AI) programs -- including ChatGPT -- have passed the U.S. Medical Licensing Examination (USMLE), according to two recent papers. https://t.co/E5GEWrJR00 https://t.co/nd9PrLVn4U

VEXAS may be more common than expected A great study of a recently described rheumatologic/hematologic disorder VEXAS syndrome recently appeared in JAMA, describing the frequency and presentations of UBA1 variant. https://t.co/HeYdjTKiqV https://t.co/T7lKHaQU3Z